Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...

Investing.com - Jefferies raised its price target on Pyxis Oncology Inc. (NASDAQ:PYXS) to $8.00 from $7.40 while maintaining a Buy rating on the stock. The new target represents significant upside ...

Investing.com - William Blair reiterated a Market Perform rating on Pyxis Oncology Inc. (NASDAQ:PYXS) stock. The stock has declined nearly 12% over the past week, currently trading at $1.46 with a ...

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...

Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker and dry-bulk sectors in the United States and internationally. It operates through two segments: Tanker ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

Pyxis One, a California-based tech startup that aims to revolutionize marketing and consumer intelligence by providing an all-in-one, codeless AI platform, closed $17M in Series B funding. With total ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.